Worst Biopharma CEO of 2024? It’s no contest

Remi Barbier, the former — and currently disgraced — CEO of Cassava Sciences, is the Worst Biopharma CEO of 2024.

He’s also the easiest, most obvious selection I’ve ever made for this particular dishonor, something I’ve been doing annually for 17 years.

Barbier had a bad year. Cassava’s Alzheimer’s drug candidate simufilam proved to be nothing more than a placebo in a large clinical trial. The company blew up. He lost his job. He was penalized by the Securities and Exchange Commission. And he remains a defendant in ongoing shareholder and class-action lawsuits.

STAT+ Exclusive Story

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

Navigating challenges of bringing cell and gene therapies to market

T-cells are highly effective at attacking cancer cells, but regulatory obstacles must be overcome to ensure that patients can benefit from treatments. Credit: Andrea Danti

July 22, 2024

How Masimo forced Apple to redesign its smartwatches

Joe Kiani, Masimo founder and CEO, has taken on one of the world’s largest companies and is not backing down in an intellectual property battle

January 26, 2024

Genetic testing: A game-changer for healthcare

As genetic sequencing technology becomes more accessible and efficient, researchers have made significant strides in understanding the genetic underpinnings of various diseases. This knowledge has

September 5, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.